|
1.
|
Takakura S, Takano M, Takahashi F, Saito
T, Aoki D, Inaba N, Noda K, Sugiyama T and Ochiai K; Japanese
Gynecologic Oncology Group: Randomized phase II trial of paclitaxel
plus carboplatin therapy versus irinotecan plus cisplatin therapy
as first-line chemotherapy for clear cell adenocarcinoma of the
ovary: a JGOG study. Int J Gynecol Cancer. 20:240–247. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Shimada M, Kigawa J, Ohishi Y, Yasuda M,
Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T and Kaku T:
Clinicopathological characteristics of mucinous adenocarcinoma of
the ovary. Gynecol Oncol. 113:331–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Katsumata N, Yasuda M, Takahashi F,
Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura
E, Ochiai K and Noda K; Japanese Gynecologic Oncology Group:
Dose-dense paclitaxel once a week in combination with carboplatin
every 3 weeks for advanced ovarian cancer: a phase 3, open-label,
randomised controlled trial. Lancet. 374:1331–1338. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Armstrong DK, Bundy B, Wenzel L, Huang HQ,
Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA:
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl
J Med. 354:34–43. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Barbieri F, Lorenzi P, Ragni N, Schettini
G, Bruzzo C, Pedullà F and Alama A: Overexpression of cyclin D1 is
associated with poor survival in epithelial ovarian cancer.
Oncology. 66:310–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
NIH Consensus Conference: Ovarian cancer.
Screening, treatment, and follow-up. JAMA. 273:491–497. 1995.
View Article : Google Scholar
|
|
7.
|
Terauchi F, Nishi H, Moritake T, et al:
Prognostic factor on optimal debulking surgery by maximum effort
for stage IIIC epithelial ovarian cancer. J Obstet Gynaecol Res.
35:315–319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Du Bois A, Reuss A, Pujade-Lauraine E,
Harter P, Ray-Coquard I and Pfisterer J: Role of surgical outcome
as prognostic factor in advanced epithelial ovarian cancer: a
combined exploratory analysis of 3 prospectively randomized phase 3
multicenter trials: by the Arbeitsgemeinschaft Gynaekologische
Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe
d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire
(GINECO). Cancer. 115:1234–1244. 2009.
|
|
9.
|
Chi DS, Eisenhauer EL, Zivanovic O, et al:
Improved progression-free and overall survival in advanced ovarian
cancer as a result of a change in surgical paradigm. Gynecol Oncol.
114:26–31. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Etemadmoghadam D, deFazio A, Beroukhim R,
Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB,
Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, Chiew
YE, Traficante N, Fereday S, Johnson D, Fox S, Sellers W, Urashima
M, Salvesen HB, Meyerson M and Bowtell D; AOCS Study Group:
Integrated copy number and expression analysis of chemoresistant
ovarian carcinomas. Clin Cancer Res. 15:1417–1427. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Bali A, O’Brien PM, Edwards LS, Sutherland
RL, Hacker NF and Henshall SM: Cyclin D1, p53, and
p21Waf1/Cip1 expression is predictive of poor clinical
outcome in serous epithelial ovarian cancer. Clin Cancer Res.
10:5168–5177. 2004.
|
|
12.
|
Psyrri A, Bamias A, Yu Z, et al:
Subcellular localization and protein levels of cyclin-dependent
kinase inhibitor p27 independently predict for survival in
epithelial ovarian cancer. Clin Cancer Res. 11:8384–8390. 2005.
View Article : Google Scholar
|
|
13.
|
Khouja MH, Baekelandt M, Nesland JM and
Holm R: The clinical importance of Ki-67, p16, p14, and p57
expression in patients with advanced ovarian carcinoma. Int J
Gynecol Pathol. 26:418–425. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Milde-Langosch K and Riethdorf S: Role of
cell-cycle regulatory proteins in gynecological cancer. J Cell
Physiol. 196:224–244. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Kommoss S, du Bois A, Ridder R, Trunk MJ,
Schmidt D, Pfisterer J and Kommoss F; AGO-OVAR: Independent
prognostic significance of cell cycle regulator proteins p16(INK4a)
and pRb in advanced-stage ovarian carcinoma including optimally
debulked patients: a translational research subprotocol of a
randomised study of the Arbeitsgemeinschaft Gynaekologische
Onkologie Ovarian Cancer Study Group. Br J Cancer. 96:306–313.
2007.
|
|
16.
|
Sherr CJ: G1 phase progression: cycling on
cue. Cell. 79:551–555. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Dhar KK, Branigan K, Parkes J, et al:
Expression and subcellular localization of cyclin D1 protein in
epithelial ovarian tumour cells. Br J Cancer. 81:1174–1181. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Worsley SD, Ponder BA and Davies BR:
Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol
Oncol. 64:189–195. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Barbieri F, Cagnoli M, Ragni N, Foglia G,
Bruzzo C, Pedullà F and Alama A: Increased cyclin D1 expression is
associated with features of malignancy and disease recurrence in
ovarian tumors. Clin Cancer Res. 5:1837–1842. 1999.PubMed/NCBI
|
|
20.
|
Masciullo V, Scambia G, Marone M, et al:
Altered expression of cyclin D1 and CDK4 genes in ovarian
carcinomas. Int J Cancer. 74:390–395. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Diebold J, Mösinger K, Peiro G, et al:
20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence
in situ hybridization. J Pathol. 190:564–571. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Jiang Q, Feng MG and Mo YY: Systematic
validation of predicted microRNAs for cyclin D1. BMC Cancer.
9:1942009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Zhou X, Zhang Z, Yang X, Chen W and Zhang
P: Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human
oral squamous cell carcinoma cells is associated with increased
cisplatin chemosensitivity. Int J Cancer. 124:483–489. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Biliran H Jr, Wang Y, Banerjee S, et al:
Overexpression of cyclin D1 promotes tumor cell growth and confers
resistance to cisplatin-mediated apoptosis in an elastase-myc
transgene-expressing pancreatic tumor cell line. Clin Cancer Res.
11:6075–6086. 2005. View Article : Google Scholar
|
|
25.
|
Blain SW, Scher HI, Cordon-Cardo C and
Koff A: p27 as a target for cancer therapeutics. Cancer Cell.
3:111–115. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Nam EJ and Kim YT: Alteration of
cell-cycle regulation in epithelial ovarian cancer. Int J Gynecol
Cancer. 18:1169–1182. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Shigemasa K, Shiroyama Y, Sawasaki T, et
al: Underexpression of cyclin-dependent kinase inhibitor p27 is
associated with poor prognosis in serous ovarian carcinomas. Int J
Oncol. 18:953–958. 2001.PubMed/NCBI
|
